News Brent Saunders ejects from Bausch + Lomb once again Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
News Bausch + Lomb drug fails in glaucoma, but a new use beckons Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.
News Bausch + Lomb dips on rumour of failing takeover talks Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.
News Bausch + Lomb buys US rights to Stada's Lucentis biosimilar Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte
News Brent Saunders ejects from Bausch + Lomb once again Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
